Soleus Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Soleus Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-169,000	Closed	-$8.17M	–	99
2025 Q1	$8.17M	Sell	169,000 -106,000	-39%	-$4.44M	0.59%	42
2024 Q4	$10.6M	Buy	+275,000	New	+$12M	0.67%	38
2024 Q2	–	Sell	-34,500	Closed	-$998K	–	107
2024 Q1	$998K	Sell	34,500 -48,500	-58%	-$1.32M	0.07%	82
2023 Q4	$1.9M	Buy	+83,000	New	+$1.45M	0.21%	55
2023 Q3	–	Sell	-39,800	Closed	-$1.1M	–	109
2023 Q2	$1.1M	Buy	+39,800	New	+$996K	0.12%	83
2023 Q1	–	Sell	-236,000	Closed	-$2.57M	–	94
2022 Q4	$2.57M	Buy	+236,000	New	+$1.99M	0.37%	52

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Soleus Capital Management's PTGX Position: Q2 2025 in Review

Soleus Capital Management sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 169,000 shares — an estimated $8.17M sold.

Soleus Capital Management first reported a position in PTGX in Q4 2022 and held it in 6 quarters. The position peaked at $10.6M in Q4 2024. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

Soleus Capital Management reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
Soleus Capital Management sold 169,000 Protagonist Therapeutics shares in Q2 2025, an estimated $8.17M.
Soleus Capital Management first reported a position in Protagonist Therapeutics in Q4 2022 and held it in 6 quarters.
Soleus Capital Management's Protagonist Therapeutics position peaked at $10.6M in Q4 2024.
272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Soleus Capital Management's 13F filing for Q2 2025, filed 15 Aug 2025.